Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer.

EMBO Mol Med · 2018 · PMC5991591 · PMID 29848757

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Patients with low levels of EGFR ‐activating mutations pre‐treatment tended to have better progression‐free survival (PFS) and overall survival (OS; Fig 2 A and B), though this did not reach statistical significance level of 0.05 (their corresponding Cox P ‐values were 0.06 for both PFS and OS).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.